MINNEAPOLIS, Oct. 9, 2012 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today announced that at the October 7-10, 2012 Annual Meeting of the Western Section of the American Urological Association in Waikoloa, HI, there will be two presentations on Uroplasty's Urgent® PC Neuromodulation System.
Dr. Kenneth M. Peters, MD, Beaumont Hospital, Royal Oak, MI will present:
"We are pleased to have the 3-year STEP Study data presented for the first time," said David Kaysen, President and CEO of Uroplasty. "Dr. Kenneth Peters has been the lead investigator on this and previous clinical studies that established the safety and effectiveness of PTNS using the Urgent PC Neuromodulation System. This multi-center study demonstrated that patients, who respond to the initial 12 weeks of Urgent PC therapy, sustained their symptom improvement over 3 years.
"The SUmiT Trial originally proved that PTNS efficacy is superior to a validated sham procedure. Dr. Peters will present results of further data analysis of the SUmiT Trial which reiterate that PTNS is an effective treatment for patients with OAB," continued Mr. Kaysen.
"The safety and efficacy of PTNS was also reinforced by the recently published AUA Guidelines Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults which include PTNS as an essential part of the OAB algorithm of care," concluded Mr. Kaysen.
About Uroplasty, Inc.
Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom is a global medical company committed to offering transformative treatment options to specialty physicians. Our products are designed to help providers change the lives of their voiding dysfunction patients and strengthen the efficiency of their practices. Our focus is the continued commercialization of our Urgent® PC Neuromodulation System, the only FDA-cleared system that delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder and associated symptoms of urgency, frequency and urge incontinence. We also offer Macroplastique®, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at www.uroplasty.com.
This press release contains forward-looking statements that reflect our best estimates regarding future events and financial performance. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our anticipated results. We discuss in detail the factors that may affect the achievement of our forward-looking statements in our Annual Report on Form 10-K filed with the SEC. In particular, we cannot be certain that the rate of reimbursement for PTNS treatments will be adequate to justify the cost of our product, that other Medicare carriers or private payers will provide coverage for this treatment, or that any of the other risks identified in our 10-K will not adversely affect our expectations as described in these forward-looking statements.
For Further Information:
David Kaysen, President and CEO, or
Medi Jiwani, Vice President, CFO, Treasurer
Doug Sherk/Jenifer Kirtland (Investors),
Chris Gale (Media), 646.201.5431
SOURCE Uroplasty, Inc.